Abstract
Despite recent advances in therapy, subgroups of multiple myeloma continue to have a poor prognosis. Numerous epigenetic changes have been described and occur as both etiologic and secondary events, making myeloma a good disease in which to understand the role of epigenetic therapies. Here, we describe a number of current and potential epigenetic targets in myeloma.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acetylation / drug effects
-
B-Lymphocytes / cytology
-
DNA (Cytosine-5-)-Methyltransferases / antagonists & inhibitors
-
DNA Methylation / drug effects
-
Epigenesis, Genetic / genetics*
-
Histone Deacetylase Inhibitors / pharmacology
-
Histone Demethylases / antagonists & inhibitors
-
Histone Methyltransferases
-
Histone-Lysine N-Methyltransferase / antagonists & inhibitors
-
Humans
-
Multiple Myeloma / genetics*
-
Multiple Myeloma / therapy*
Substances
-
Histone Deacetylase Inhibitors
-
Histone Demethylases
-
Histone Methyltransferases
-
DNA (Cytosine-5-)-Methyltransferases
-
Histone-Lysine N-Methyltransferase